Source author record

Ewout W. Steyerberg

Ewout W. Steyerberg appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

3works
2topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

3 published item(s)

preprint2022arXiv

A standardized framework for risk-based assessment of treatment effect heterogeneity in observational healthcare databases

The Predictive Approaches to Treatment Effect Heterogeneity statement focused on baseline risk as a robust predictor of treatment effect and provided guidance on risk-based assessment of treatment effect heterogeneity in the RCT setting. The aim of this study was to extend this approach to the observational setting using a standardized scalable framework. The proposed framework consists of five steps: 1) definition of the research aim, i.e., the population, the treatment, the comparator and the outcome(s) of interest; 2) identification of relevant databases; 3) development of a prediction model for the outcome(s) of interest; 4) estimation of relative and absolute treatment effect within strata of predicted risk, after adjusting for observed confounding; 5) presentation of the results. We demonstrate our framework by evaluating heterogeneity of the effect of angiotensin-converting enzyme (ACE) inhibitors versus beta blockers on three efficacy and six safety outcomes across three observational databases. The proposed framework can supplement any comparative effectiveness study. We provide a publicly available R software package for applying this framework to any database mapped to the Observational Medical Outcomes Partnership Common Data Model. In our demonstration, patients at low risk of acute myocardial infarction received negligible absolute benefits for all three efficacy outcomes, though they were more pronounced in the highest risk quarter, especially for hospitalization with heart failure. However, failing diagnostics showed evidence of residual imbalances even after adjustment for observed confounding. Our framework allows for the evaluation of differential treatment effects across risk strata, which offers the opportunity to consider the benefit-harm trade-off between alternative treatments.

preprint2022arXiv

Individualized treatment effect was predicted best by modeling baseline risk in interaction with treatment assignment

Objective: To compare different risk-based methods for optimal prediction of treatment effects. Methods: We simulated RCT data using diverse assumptions for the average treatment effect, a baseline prognostic index of risk (PI), the shape of its interaction with treatment (none, linear, quadratic or non-monotonic), and the magnitude of treatment-related harms (none or constant independent of the PI). We predicted absolute benefit using: models with a constant relative treatment effect; stratification in quarters of the PI; models including a linear interaction of treatment with the PI; models including an interaction of treatment with a restricted cubic spline (RCS) transformation of the PI; an adaptive approach using Akaike's Information Criterion. We evaluated predictive performance using root mean squared error and measures of discrimination and calibration for benefit. Results: The linear-interaction model displayed optimal or close-to-optimal performance across many simulation scenarios with moderate sample size (N=4,250 patients; ~ 785 events). The RCS-model was optimal for strong non-linear deviations from a constant treatment effect, particularly when sample size was larger (N=17,000). The adaptive approach also required larger sample sizes. These findings were illustrated in the GUSTO-I trial. Conclusion: An interaction between baseline risk and treatment assignment should be considered to improve treatment effect predictions.

preprint2015arXiv

Personalized Screening Intervals for Biomarkers using Joint Models for Longitudinal and Survival Data

Screening and surveillance are routinely used in medicine for early detection of disease and close monitoring of progression. Biomarkers are one of the primarily tools used for these tasks, but their successful translation to clinical practice is closely linked to their ability to accurately predict clinical endpoints during follow-up. Motivated by a study of patients who received a human tissue valve in the aortic position, in this work we are interested in optimizing and personalizing screening intervals for longitudinal biomarker measurements. Our aim in this paper is twofold: First, to appropriately select the model to use at time t, the time point the patient was still event-free, and second, based on this model to select the optimal time point u > t to plan the next measurement. To achieve these two goals we develop measures based on information theory quantities that assess the information we gain for the conditional survival process given the history of the subject that includes both baseline information and his/her accumulated longitudinal measurements.